TGTX: Q2 2026 revenue surged 64% year-over-year, driving raised full-year guidance and strong liquidity
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw global revenue reach $240.3 million, with BRIUMVI U.S. net product revenue up 64% year-over-year. Full-year 2026 revenue guidance was raised, and positive clinical progress supports future growth. Cash reserves remain strong at $612.3 million.Original document: TG Therapeutics, Inc. [TGTX] SEC 8-K Current Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw global revenue reach $240.3 million, with BRIUMVI U.S. net product revenue up 64% year-over-year. Full-year 2026 revenue guidance was raised, and positive clinical progress supports future growth. Cash reserves remain strong at $612.3 million.
Original document: TG Therapeutics, Inc. [TGTX] SEC 8-K Current Report — Aug. 3 2026